CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo
Cancer Research and Treatment. 2019;51(3):951-962.   Published online 2018 October 10    DOI: https://doi.org/10.4143/crt.2018.052

Excel Download

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib
Cancer Research and Treatment. 2019;51(3):951-962   Crossref logo
Link1 Link2 Link3

Acquired resistance mechanisms to INC280, a MET inhibitor in MET-amplified lung cancer cells
European Journal of Cancer. 2016;69:S135-S136   Crossref logo
Link1 Link2

AXL/MET dual inhibitor, CB469, has activity in non-small cell lung cancer with acquired resistance to EGFR TKI with AXL or MET activation
Lung Cancer. 2020;146:70-77   Crossref logo
Link1 Link2

Interstitial lung disease associated with capmatinib therapy in a patient with nonā€small cell lung cancer harboring a skipping mutation of MET exon 14
Thoracic Cancer. 2020;12(4):549-552   Crossref logo
Link1 Link2 Link3

JCES01.16 A MET Inhibitor in the Treatment of Metastatic Non-Small Cell Lung Cancer with MET Amplification
Journal of Thoracic Oncology. 2017;12(1):S236   Crossref logo
Link1 Link2

Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Lung Cancer: Targets and Therapy. 2021;Volume 12:11-20   Crossref logo
Link1 Link2

P3.02c-008 A MET Inhibitor in the Treatment of Metastatic Non-Small Cell Lung Cancer with MET Amplification
Journal of Thoracic Oncology. 2017;12(1):S1276   Crossref logo
Link1 Link2

Capmatinib for patients with non-small cell lung cancer with MET exon 14 skipping mutations: A review of preclinical and clinical studies
Cancer Treatment Reviews. 2021;95:102173   Crossref logo
Link1 Link2

O.04: Profiling of MET-Amplified Non-Small Cell Lung Cancer (NSCLC), Correlation to cMET Protein Expression/MET Exon 14 Skipping
Journal of Thoracic Oncology. 2016;11(10):S170   Crossref logo
Link1 Link2

26PD FORETINIB (GSK1363089), A MULTIKINASE INHIBITOR OF MET AND VEGFS, OVERCOMES RESISTANCE TO BEVACIZUMAB IN AN IN VIVO MODEL OF ACQUIRED BEVACIZUMAB RESISTANCE
Lung Cancer. 2013;80:S11-S12   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Cancer Res Treat has participated in CrossRef Text and Data Mining service since October 29, 2014.